Payment overview · 2025
General Payments
$579.86
25 reported records · 11 companies
Healthcare provider profile · identity verified
Jim R Wade, MD
Allopathic & Osteopathic Physicians|Internal Medicine · TOCCOA, GA · NPI 1700860913
Verified facts
What the public records show
CMS Open Payments records show Jim R Wade, MD received $579.86 in general payments during 2025 across 25 reported records.
Novo Nordisk Inc accounted for 37.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 341 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $217.60 | 37.5% | 7 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $77.26 | 13.3% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $48.29 | 8.3% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $44.98 | 7.8% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $39.24 | 6.8% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $33.90 | 5.8% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $31.90 | 5.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $31.66 | 5.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.71 | 3.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.36 | 3.2% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.96 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $579.86 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $143.66 | 3 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $77.26 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $60.49 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $60.49 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $44.98 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $44.98 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $39.24 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $33.90 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $33.90 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $31.90 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $24.77 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $23.52 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $22.71 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $22.71 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.36 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.36 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.04 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $13.96 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 341 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 71 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
52 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
71 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
99 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
341 | 39 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 920 | 123 |
| Famotidine | Famotidine | 835 | 58 |
| Quetiapine Fumarate | Quetiapine Fumarate | 707 | 45 |
| Atorvastatin Calcium | Atorvastatin Calcium | 600 | 93 |
| Levothyroxine Sodium | Levothyroxine Sodium | 599 | 90 |
| Sertraline Hcl | Sertraline Hcl | 554 | 42 |
| Pravastatin Sodium | Pravastatin Sodium | 551 | 36 |
| Losartan Potassium | Losartan Potassium | 517 | 121 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 514 | 134 |
| Furosemide | Furosemide | 500 | 73 |
| Metoprolol Tartrate | Metoprolol Tartrate | 497 | 50 |
| Lisinopril | Lisinopril | 444 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 444 | 54 |
| Gabapentin | Gabapentin | 435 | 41 |
| Montelukast Sodium | Montelukast Sodium | 435 | 29 |
| Carvedilol | Carvedilol | 427 | 33 |
| Potassium Chloride | Potassium Chloride | 399 | 52 |
| Omeprazole | Omeprazole | 367 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 364 | 55 |
| Donepezil Hcl | Donepezil Hcl | 359 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 359 | 32 |
| Eliquis | Apixaban | 341 | 39 |
| Divalproex Sodium | Divalproex Sodium | 338 | suppressed |
| Metformin Hcl | Metformin Hcl | 329 | 51 |
| Clopidogrel | Clopidogrel Bisulfate | 313 | 33 |
| Mirtazapine | Mirtazapine | 292 | 21 |
| Trazodone Hcl | Trazodone Hcl | 287 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 286 | 47 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 264 | 38 |
| Olanzapine | Olanzapine | 238 | suppressed |
| Glipizide | Glipizide | 236 | 36 |
| Clonidine Hcl | Clonidine Hcl | 228 | 17 |
| Memantine Hcl | Memantine Hcl | 223 | 27 |
| Risperidone | Risperidone | 214 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 204 | 16 |
| Simvastatin | Simvastatin | 179 | 47 |
| Spironolactone | Spironolactone | 175 | 39 |
| Valsartan | Valsartan | 170 | 11 |
| Sucralfate | Sucralfate | 163 | 18 |
| Allopurinol | Allopurinol | 157 | 28 |
| Digoxin | Digoxin | 144 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 142 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 120 | 31 |
| Buspirone Hcl | Buspirone Hcl | 114 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 112 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 110 | 23 |
| Doxazosin Mesylate | Doxazosin Mesylate | 109 | 31 |
| Finasteride | Finasteride | 108 | 15 |
| Meloxicam | Meloxicam | 105 | 26 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 104 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 103 | suppressed |
| Jardiance | Empagliflozin | 99 | 14 |
| Ziprasidone Hcl | Ziprasidone Hcl | 99 | suppressed |
| Alprazolam | Alprazolam | 97 | 20 |
| Lorazepam | Lorazepam | 95 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 84 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 79 | suppressed |
| Lamotrigine | Lamotrigine | 79 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 79 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 75 | 12 |
| Atenolol | Atenolol | 74 | 18 |
| Clonazepam | Clonazepam | 74 | suppressed |
| Xarelto | Rivaroxaban | 74 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 73 | 19 |
| Ezetimibe | Ezetimibe | 72 | suppressed |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 71 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 71 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 71 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 70 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 69 | 25 |
| Metformin Hcl Er | Metformin Hcl | 64 | 19 |
| Levemir Flexpen | Insulin Detemir | 62 | 12 |
| Unifine Safecontrol Pen Needle | Pen Needle,dual Safety,diabetc | 62 | suppressed |
| Fenofibrate | Fenofibrate | 61 | 13 |
| Midodrine Hcl | Midodrine Hcl | 60 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 58 | suppressed |
| Nifedipine Er | Nifedipine | 58 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 54 | suppressed |
| Tradjenta | Linagliptin | 54 | suppressed |
| Glipizide Er | Glipizide | 53 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 52 | suppressed |
| Synthroid | Levothyroxine Sodium | 52 | 12 |
| Terazosin Hcl | Terazosin Hcl | 52 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 51 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 51 | suppressed |
| Phenytoin | Phenytoin | 51 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 51 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 50 | 12 |
| Januvia | Sitagliptin Phosphate | 50 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 49 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 49 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 48 | 15 |
| Flecainide Acetate | Flecainide Acetate | 48 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 48 | suppressed |
| Nifedipine | Nifedipine | 46 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 46 | 34 |
| Oxybutynin Chloride | Oxybutynin Chloride | 45 | suppressed |
| Bumetanide | Bumetanide | 43 | suppressed |
| Celecoxib | Celecoxib | 43 | suppressed |
| Pregabalin | Pregabalin | 43 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 42 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 42 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 42 | 11 |
| Latanoprost | Latanoprost | 41 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 41 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 32 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 37 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | 11 |
| Cephalexin | Cephalexin | 36 | 22 |
| Mounjaro | Tirzepatide | 35 | suppressed |
| Azithromycin | Azithromycin | 34 | 30 |
| Pioglitazone Hcl | Pioglitazone Hcl | 34 | suppressed |
| Carbamazepine | Carbamazepine | 33 | suppressed |
| Haloperidol | Haloperidol | 33 | suppressed |
| Levofloxacin | Levofloxacin | 33 | 25 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 33 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Acyclovir | Acyclovir | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Prednisone | Prednisone | 30 | 13 |
| Torsemide | Torsemide | 30 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Naproxen | Naproxen | 28 | suppressed |
| Novolog Flexpen | Insulin Aspart | 28 | suppressed |
| Ozempic | Semaglutide | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Baclofen | Baclofen | 27 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 25 | suppressed |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 25 | suppressed |
| Temazepam | Temazepam | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 13 |
| Colchicine | Colchicine | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Novolog | Insulin Aspart | 24 | suppressed |
| Praluent Pen | Alirocumab | 23 | suppressed |
| Cefdinir | Cefdinir | 22 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 17 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 20 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 19 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 17 | 17 |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Eplerenone | Eplerenone | 17 | suppressed |
| Nadolol | Nadolol | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Phenobarbital | Phenobarbital | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Fluconazole | Fluconazole | 15 | 14 |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 15 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 12 |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 13 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Oxazepam | Oxazepam | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Glucagon Emergency Kit | Glucagon | 11 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $579.86 · 25 records | Novo Nordisk Inc | AIRSUPRA, CAPLYTA, CAPVAXIVE, ELIQUIS, FARXIGA, GARDASIL 9, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, TRINTELLIX, UBRELVY, Wegovy, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error